Figure 1 | Scientific Reports

Figure 1

From: DYRK1A antagonists rescue degeneration and behavioural deficits of in vivo models based on amyloid-β, Tau and DYRK1A neurotoxicity

Figure 1

DYRK1A inhibitors reduced phosphorylation of human Tau expressed pan-neuronally in Drosophila. Western blots show effects of treatment with DYRK1A inhibitors (DYR219 and DYR533) on phosphorylation of human Tau 0N4R overexpressed pan-neuronally using the elav-Gal4 driver: 1st lane is Elav-Gal4/ + control, 2nd lane is Elav > human Tau 0N4R with normal food, 3rd lane is Elav > human Tau treated with 304 μM DYR219 and 4th lane is Elav > human Tau with 248 μM DYR533 treatment throughout development and adulthood (treatments were the same for all subsequent figures). Three antibodies against phosphorylated Tau (pS262, pS396 and pT231) were tested compared to the level of total unphosphorylated Tau (~ 55 kDa) using a fourth antibody. At the bottom is the β-actin protein loading control (~ 42 kDa). Supplemental Fig. S1 shows the full Westerns that the bands were imaged from. Intensity of bands are presented as mean ± Standard Error of the Mean (SEM) with data compared by 2-way ANOVA with Dunnett's multiple comparisons test **P < 0.01 and ***P < 0.001.

Back to article page